Profound Medical (TSE:PRN) Posts Earnings Results

Profound Medical (TSE:PRN) issued its earnings results on Thursday. The company reported C$0.26 earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of C$7.42 million for the quarter. Profound Medical had a negative return on equity of 85.73% and a negative net margin of 248.45%.

Profound Medical Stock Performance

TSE PRN opened at C$9.42 on Friday. The company has a debt-to-equity ratio of 7.09, a current ratio of 12.52 and a quick ratio of 14.98. Profound Medical has a 1-year low of C$5.23 and a 1-year high of C$12.40. The business has a 50 day simple moving average of C$8.78 and a two-hundred day simple moving average of C$9.29. The stock has a market capitalization of C$341.89 million, a PE ratio of -6.68 and a beta of 1.00.

Insider Activity

In other news, Director Dr. Arun Menawat acquired 20,000 shares of the firm’s stock in a transaction dated Friday, March 20th. The shares were acquired at an average cost of C$6.96 per share, with a total value of C$139,200.00. Following the acquisition, the director directly owned 658,660 shares of the company’s stock, valued at approximately C$4,584,273.60. The trade was a 3.13% increase in their ownership of the stock. 8.62% of the stock is owned by company insiders.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.